JP6110309B2 - 造血幹細胞の生着を増進させるための方法 - Google Patents

造血幹細胞の生着を増進させるための方法 Download PDF

Info

Publication number
JP6110309B2
JP6110309B2 JP2013548848A JP2013548848A JP6110309B2 JP 6110309 B2 JP6110309 B2 JP 6110309B2 JP 2013548848 A JP2013548848 A JP 2013548848A JP 2013548848 A JP2013548848 A JP 2013548848A JP 6110309 B2 JP6110309 B2 JP 6110309B2
Authority
JP
Japan
Prior art keywords
cells
bone marrow
treprostinil
stem cells
hematopoietic stem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013548848A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507409A (ja
Inventor
フライッスムト，ミヒャエル
ツェベディン−ブランデル，エファ−マリア
ベルクマイル，クリスティアン
フセイン，フィルツァ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scipharm SARL
Original Assignee
Scipharm SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44146841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6110309(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scipharm SARL filed Critical Scipharm SARL
Publication of JP2014507409A publication Critical patent/JP2014507409A/ja
Application granted granted Critical
Publication of JP6110309B2 publication Critical patent/JP6110309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
JP2013548848A 2011-01-13 2012-01-13 造血幹細胞の生着を増進させるための方法 Active JP6110309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11150835 2011-01-13
EP11150835.4 2011-01-13
PCT/EP2012/050484 WO2012095511A1 (en) 2011-01-13 2012-01-13 Method for enhancing engraftment of haematopoetic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016204970A Division JP2017046707A (ja) 2011-01-13 2016-10-19 造血幹細胞の生着を増進させるための方法

Publications (2)

Publication Number Publication Date
JP2014507409A JP2014507409A (ja) 2014-03-27
JP6110309B2 true JP6110309B2 (ja) 2017-04-05

Family

ID=44146841

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013548848A Active JP6110309B2 (ja) 2011-01-13 2012-01-13 造血幹細胞の生着を増進させるための方法
JP2016204970A Withdrawn JP2017046707A (ja) 2011-01-13 2016-10-19 造血幹細胞の生着を増進させるための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016204970A Withdrawn JP2017046707A (ja) 2011-01-13 2016-10-19 造血幹細胞の生着を増進させるための方法

Country Status (19)

Country Link
US (1) US10213464B2 (https=)
EP (1) EP2663313B1 (https=)
JP (2) JP6110309B2 (https=)
KR (1) KR101950526B1 (https=)
CN (1) CN103379907B (https=)
AU (1) AU2012206517B2 (https=)
BR (1) BR112013017878B1 (https=)
CA (1) CA2824113C (https=)
CL (1) CL2013002034A1 (https=)
DK (1) DK2663313T3 (https=)
EA (1) EA033717B1 (https=)
ES (1) ES2693622T3 (https=)
IL (1) IL227331A (https=)
PL (1) PL2663313T3 (https=)
PT (1) PT2663313T (https=)
SG (1) SG191908A1 (https=)
UA (1) UA113284C2 (https=)
WO (1) WO2012095511A1 (https=)
ZA (1) ZA201304743B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2879682B1 (en) * 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
EP3712142B1 (en) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
AU2015217142B2 (en) * 2014-02-12 2020-04-09 7 Hills Pharma LLC Compositions and methods to improve the homing and grafting of hematopoetic stem cells
CA2946747A1 (en) * 2014-04-23 2015-10-29 Texas Heart Institute Methods of enhancing stem cell engraftment
US10226465B2 (en) * 2015-01-27 2019-03-12 Scipharm Sàrl Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL262720B2 (en) 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
CN109727671B (zh) * 2018-12-28 2021-07-09 广东省心血管病研究所 一种鉴定造血干细胞移植术效果的信息分析系统及方法
WO2025172541A1 (en) 2024-02-15 2025-08-21 Aop Orphan Pharmaceuticals Gmbh New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US6242482B1 (en) * 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US8696564B2 (en) 2004-07-09 2014-04-15 Cardiac Pacemakers, Inc. Implantable sensor with biocompatible coating for controlling or inhibiting tissue growth
US20070065414A1 (en) * 2005-09-16 2007-03-22 Boston Scientific Scimed, Inc. Enhanced delivery of cells
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
US8575175B2 (en) * 2008-07-23 2013-11-05 Toray Industries, Inc. Therapeutic agent for chronic renal failure
CN102164487A (zh) * 2008-09-25 2011-08-24 阿拉迪姆公司 曲前列素的深肺部递送
CN108379292A (zh) 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
WO2010108028A2 (en) 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
RS53234B (sr) * 2009-08-07 2014-08-29 Scipharm Sàrl Kompozicija za lečenje cistične fibroze

Also Published As

Publication number Publication date
EP2663313A1 (en) 2013-11-20
JP2017046707A (ja) 2017-03-09
CN103379907B (zh) 2018-01-09
ES2693622T3 (es) 2018-12-13
JP2014507409A (ja) 2014-03-27
ZA201304743B (en) 2014-09-25
DK2663313T3 (en) 2018-11-26
UA113284C2 (xx) 2017-01-10
NZ612450A (en) 2015-03-27
BR112013017878A8 (pt) 2018-01-09
US20130344038A1 (en) 2013-12-26
AU2012206517A1 (en) 2013-08-01
IL227331A0 (en) 2013-09-30
US10213464B2 (en) 2019-02-26
IL227331A (en) 2017-12-31
EA201300817A1 (ru) 2013-11-29
SG191908A1 (en) 2013-08-30
KR101950526B1 (ko) 2019-02-20
PT2663313T (pt) 2018-10-23
CL2013002034A1 (es) 2014-03-21
BR112013017878A2 (https=) 2017-08-15
CN103379907A (zh) 2013-10-30
KR20140005956A (ko) 2014-01-15
PL2663313T3 (pl) 2019-01-31
EP2663313B1 (en) 2018-08-08
EA033717B1 (ru) 2019-11-19
WO2012095511A1 (en) 2012-07-19
AU2012206517B2 (en) 2016-12-01
CA2824113A1 (en) 2012-07-19
BR112013017878B1 (pt) 2021-08-31
CA2824113C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
JP6110309B2 (ja) 造血幹細胞の生着を増進させるための方法
JP6669762B2 (ja) 移植後の造血幹細胞の生着効率の増進に使用するための組成物
ES2538305T3 (es) Métodos para expandir poblaciones de células mieloides y usos de las mismas
KR102466885B1 (ko) 프로스타시클린 및 중간엽 줄기 세포를 사용한 혈관병증의 치료
EP2836214B1 (en) Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
WO2010096264A2 (en) Methods for enhancing hematopoietic stem/progenitor cell engraftment
HK1186389B (en) Method for enhancing engraftment of haematopoetic stem cells
HK1186389A (en) Method for enhancing engraftment of haematopoetic stem cells
WO2025172541A1 (en) New composition for improvement of bone marrow reconstitution and peripheral recovery of neutrophil and platelet counts
NZ612450B2 (en) Method for enhancing engraftment of haematopoetic stem cells
HK1241742B (en) Composition for use in increasing engraftment efficacy of haematopoetic stem cells after transplantation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161019

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170309

R150 Certificate of patent or registration of utility model

Ref document number: 6110309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250